Alumis' Envudeucitinib Delivers Robust Phase 3 Psoriasis Data with High PASI 90/100 Rates; NDA On Track
ALMS has more than doubled off its 52-week low of $2.76 on light trading volume (0.4× avg).
Summary
Alumis Inc. reported its first quarter 2026 financial results and provided significant updates on its clinical pipeline, most notably for envudeucitinib. The company presented late-breaking Phase 3 data for envudeucitinib in moderate-to-severe plaque psoriasis, demonstrating robust PASI 90 responses of 68.0% and 62.1% and PASI 100 responses of 41.0% and 39.5% by Week 24. These detailed results, presented at the AAD Annual Meeting, significantly reinforce the drug's potential as a leading oral therapy and further de-risk its path to market. Alumis confirmed its NDA submission for psoriasis remains on track for Q4 2026 and anticipates potentially pivotal Phase 2b topline data for envudeucitinib in systemic lupus erythematosus (SLE) in Q3 2026. The company also reported a strong cash position of $569.5 million as of March 31, 2026, providing ample runway for its development programs. Investors will be closely watching the upcoming SLE data and the planned NDA submission as key catalysts.
At the time of this announcement, ALMS was trading at $24.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $2.76 to $30.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.